A Phase 2 interventional study of PF-06700841 and Vehicle (Placebo) in Atopic Dermatitis, sponsored by Pfizer. Completed at 76 sites in 10 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 15th largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 22nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 292 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily [QD] vs twice daily [BID] application) for the future clinical development of topical PF-06700841.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06700841 0.1% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 0.3% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 1% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 3% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 0.3% cream applied twice daily (BID)
Drug: PF-06700841
PF-06700841 1% cream applied twice daily (BID)
Drug: PF-06700841
Vehicle cream applied once daily (QD)
Drug: Vehicle (Placebo)
Vehicle cream applied twice daily (BID)
Drug: Vehicle (Placebo)
PF-06700841 topical cream
Vehicle topical cream
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Time frame: Baseline, Week 6
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation
IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.
Time frame: Baseline, Week 6
Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Time frame: Baseline, Week 6
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Baseline, Weeks 1, 2, 3, 4 and 6
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit
4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.
Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Time frame: Baseline, Weeks 1, 2, 3, 4 and 6
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.
Time frame: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)
Number of Participants With Pre-defined Criteria For Vital Signs
Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.
Time frame: Baseline up to Week 6
Number of Participants With Laboratory Abnormalities
Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.
Time frame: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings
Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.
Time frame: Baseline up to Week 6
Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Change From Baseline in Lipids Profile Values at Week 6
Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.
Time frame: Baseline, Week 6
Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6
Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.
Time frame: Baseline, Week 6
Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6
Time frame: Baseline, Weeks 2 and 6
Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6
Time frame: Baseline, Weeks 2 and 6
Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6
Blood pressure included supine and sitting systolic and diastolic BP.
Time frame: Baseline, Weeks 2 and 6
Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6
Time frame: Baseline, Weeks 2 and 6
Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6
Time frame: Baseline, Weeks 2 and 6
Number of Participants With Each Severity Grade in Local Tolerability Assessments
Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent \[if still in place\]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.
Time frame: Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)
| Milestone | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Started | 37 | 37 | 36 | 37 | 36 | 36 | 36 | 37 |
| Completed | 28 | 27 | 33 | 32 | 31 | 25 | 31 | 33 |
| Not completed | 9 | 10 | 3 | 5 | 5 | 11 | 5 | 4 |
| Withdrew: Adverse event | 3 | 3 | 1 | 1 | 1 | 6 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 2 | 2 | 1 | 2 | 3 | 3 |
| Withdrew: Refused further treatment | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Started | 37 | 37 | 36 | 37 | 36 | 36 | 36 | 37 |
| Completed | 29 | 29 | 32 | 33 | 32 | 28 | 31 | 31 |
| Not completed | 8 | 8 | 4 | 4 | 4 | 8 | 5 | 6 |
| Withdrew: Adverse event | 3 | 2 | 1 | 1 | 0 | 5 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 | 3 | 2 | 2 | 2 | 3 | 3 |
| Withdrew: Refused further study procedures | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
| Percent change | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation | -44.4 (-57.3 to -31.6) | -58.3 (-71.2 to -45.5) | -64.6 (-77.1 to -52.1) | -70.1 (-82.1 to -58.0) | -67.9 (-80.6 to -55.3) | -47.6 (-57.5 to -37.7) | -58.6 (-67.5 to -49.7) | -75.0 (-83.8 to -66.2) |
IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.
| Percentage of participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation | 10.8 (4.8 to 22.2) | 29.7 (18.5 to 43.3) | 33.3 (21.3 to 47.0) | 40.5 (28.0 to 54.4) | 44.4 (30.2 to 59.1) | 13.9 (6.9 to 25.4) | 33.3 (21.3 to 47.0) | 27.0 (15.5 to 40.2) |
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
| Units on a scale | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation | -3.2 (-4.1 to -2.3) | -4.5 (-5.4 to -3.6) | -4.6 (-5.5 to -3.7) | -4.8 (-5.7 to -3.9) | -5.5 (-6.4 to -4.7) | -3.6 (-4.3 to -3.0) | -4.4 (-5.0 to -3.8) | -5.3 (-5.9 to -4.7) |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Percentage of participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| At Week 1 | 16.2 (7.3 to 29.3) | 16.7 (7.5 to 30.2) | 20.0 (11.0 to 33.8) | 29.7 (18.5 to 43.3) | 44.4 (30.2 to 59.1) | 13.9 (6.9 to 25.4) | 28.6 (16.4 to 41.9) | 25.7 (15.4 to 39.2) |
| At Week 2 | 24.3 (14.5 to 37.0) | 30.6 (18.9 to 44.0) | 42.9 (30.0 to 58.1) | 48.6 (34.3 to 63.0) | 61.1 (47.0 to 74.6) | 25.0 (14.9 to 38.0) | 45.7 (31.7 to 60.8) | 37.1 (23.6 to 52.2) |
| At Week 3 | 21.6 (11.2 to 34.3) | 38.9 (25.4 to 53.0) | 48.6 (33.8 to 63.5) | 59.5 (45.6 to 72.0) | 58.3 (44.0 to 71.0) | 33.3 (21.3 to 47.0) | 51.4 (36.5 to 66.2) | 57.1 (41.9 to 70.0) |
| At Week 4 | 35.1 (22.2 to 49.3) | 38.9 (25.4 to 53.0) | 51.4 (36.5 to 66.2) | 62.2 (48.0 to 75.2) | 58.3 (44.0 to 71.0) | 30.6 (18.9 to 44.0) | 60.0 (44.8 to 74.0) | 60.0 (44.8 to 74.0) |
| At Week 6 | 40.5 (28.0 to 54.4) | 41.7 (29.0 to 56.0) | 51.4 (36.5 to 66.2) | 56.8 (43.2 to 70.7) | 61.1 (47.0 to 74.6) | 30.6 (18.9 to 44.0) | 60.0 (44.8 to 74.0) | 60.0 (44.8 to 74.0) |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Percentage of participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| At Week 1 | 0.0 (0.0 to 8.2) | 3.3 (0.4 to 14.0) | 3.1 (0.3 to 13.1) | 16.1 (8.1 to 29.7) | 10.7 (4.0 to 23.8) | 3.3 (0.4 to 14.0) | 3.3 (0.4 to 14.0) | 11.1 (4.2 to 24.8) |
| At Week 2 | 9.1 (3.4 to 20.2) | 10.0 (3.7 to 22.1) | 9.4 (3.5 to 20.7) | 19.4 (8.8 to 32.7) | 25.0 (13.9 to 40.0) | 10.0 (3.7 to 22.1) | 13.3 (5.9 to 27.9) | 33.3 (20.4 to 50.0) |
| At Week 3 | 12.1 (5.4 to 25.1) | 23.3 (12.9 to 37.6) | 15.6 (7.8 to 28.7) | 32.3 (18.7 to 48.2) | 32.1 (19.7 to 47.3) | 10.0 (3.7 to 22.1) | 20.0 (9.1 to 33.9) | 37.0 (22.1 to 54.7) |
| At Week 4 | 18.2 (8.2 to 31.3) | 26.7 (14.0 to 41.6) | 28.1 (17.0 to 43.3) | 35.5 (21.3 to 51.8) | 50.0 (33.3 to 66.7) | 10.0 (3.7 to 22.1) | 30.0 (18.2 to 45.5) | 37.0 (22.1 to 54.7) |
| At Week 6 | 18.2 (8.2 to 31.3) | 30.0 (18.2 to 45.5) | 34.4 (20.7 to 50.0) | 45.2 (29.7 to 60.1) | 50.0 (33.3 to 66.7) | 16.7 (8.3 to 30.8) | 33.3 (19.3 to 49.2) | 40.7 (24.8 to 58.3) |
| At Follow-up visit | 9.1 (3.4 to 20.2) | 30.0 (18.2 to 45.5) | 21.9 (12.1 to 36.2) | 19.4 (8.8 to 32.7) | 21.4 (9.8 to 36.6) | 20.0 (9.1 to 33.9) | 20.0 (9.1 to 33.9) | 7.4 (2.0 to 20.4) |
4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.
| Percent change | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| At Week 1 | -2.4 (-12.2 to 7.4) | -2.9 (-12.5 to 6.8) | -16.2 (-26.2 to -6.2) | -19.9 (-29.6 to -10.2) | -23.0 (-32.8 to -13.1) | 8.5 (-8.3 to 25.3) | -16.5 (-32.9 to -0.1) | -17.0 (-33.5 to -0.5) |
| At Week 2 | -15.3 (-28.0 to -2.6) | -7.2 (-20.2 to 5.8) | -38.1 (-51.0 to -25.2) | -43.6 (-56.5 to -30.8) | -39.0 (-52.1 to -26.0) | -2.5 (-14.0 to 9.1) | -34.2 (-45.4 to -22.9) | -43.1 (-54.5 to -31.6) |
| At Week 3 | -17.1 (-31.0 to -3.1) | -13.1 (-27.4 to 1.1) | -50.6 (-64.4 to -36.7) | -55.9 (-69.7 to -42.0) | -49.2 (-63.2 to -35.1) | -25.2 (-39.2 to -11.1) | -39.8 (-53.0 to -26.6) | -44.0 (-57.1 to -30.9) |
| At Week 4 | -25.9 (-39.8 to -12.0) | -20.1 (-34.4 to -5.7) | -55.8 (-69.5 to -42.1) | -57.9 (-71.7 to -44.0) | -56.7 (-70.8 to -42.7) | -34.7 (-46.1 to -23.3) | -46.4 (-56.9 to -35.9) | -57.7 (-68.2 to -47.2) |
| At Week 6 | -21.6 (-38.0 to -5.3) | -39.4 (-56.1 to -22.7) | -59.4 (-75.4 to -43.5) | -63.6 (-79.5 to -47.6) | -60.3 (-76.4 to -44.1) | -31.2 (-42.5 to -20.0) | -48.9 (-59.3 to -38.6) | -65.0 (-75.3 to -54.7) |
| At Follow-up visit | -23.6 (-39.5 to -7.6) | -24.5 (-41.0 to -8.0) | -42.7 (-58.1 to -27.2) | -37.0 (-52.6 to -21.4) | -55.2 (-71.8 to -38.6) | -26.3 (-47.5 to -5.2) | -31.6 (-52.0 to -11.3) | -24.6 (-45.2 to -4.1) |
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
| Percentage of participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| At Week 1 | 5.4 (1.4 to 15.5) | 0.0 (0.0 to 7.3) | 19.4 (10.7 to 32.8) | 5.4 (1.4 to 15.5) | 16.7 (7.5 to 30.2) | 0.0 (0.0 to 7.5) | 13.9 (6.9 to 25.4) | 21.6 (11.2 to 34.3) |
| At Week 2 | 8.1 (3.0 to 18.5) | 10.8 (4.8 to 22.2) | 27.8 (15.9 to 40.9) | 24.3 (14.5 to 37.0) | 38.9 (25.4 to 53.0) | 13.9 (6.9 to 25.4) | 25.0 (14.9 to 38.0) | 32.4 (20.6 to 46.4) |
| At Week 3 | 5.4 (1.4 to 15.5) | 16.2 (7.3 to 29.3) | 36.1 (22.9 to 50.0) | 43.2 (29.3 to 56.8) | 41.7 (29.0 to 56.0) | 19.4 (10.7 to 32.8) | 19.4 (10.7 to 32.8) | 43.2 (29.3 to 56.8) |
| At Week 4 | 24.3 (14.5 to 37.0) | 21.6 (11.2 to 34.3) | 38.9 (25.4 to 53.0) | 43.2 (29.3 to 56.8) | 50.0 (35.3 to 64.7) | 22.2 (11.6 to 35.3) | 36.1 (22.9 to 50.0) | 48.6 (34.3 to 63.0) |
| At Week 6 | 35.1 (22.2 to 49.3) | 32.4 (20.6 to 46.4) | 52.8 (38.0 to 67.2) | 54.1 (40.2 to 68.2) | 50.0 (35.3 to 64.7) | 16.7 (7.5 to 30.2) | 36.1 (22.9 to 50.0) | 51.4 (37.0 to 65.7) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.
| Participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 18 | 17 | 11 | 12 | 10 | 17 | 9 | 14 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.
| Participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Sitting DBP: Change >= 20 mm Hg increase | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Sitting DBP: Change >= 20mmHg decrease | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Supine DBP: Value <50 mmHg | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Supine DBP: Change >= 20mmHg increase | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 0 |
| Supine DBP: Change >= 20mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Sitting SBP: <90mmHg | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Sitting SBP: change >= 30mmHg increase | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Sitting SBP: change >= 30mmHg decrease | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Supine SBP: Change >= 30mmHg increase | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 |
| Supine SBP: Change >= 30mmHg decrease | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 |
| Supine SBP: Value <90mmHg | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.
| Participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 26 | 22 | 23 | 22 | 16 | 21 | 24 | 24 |
Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.
| Participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| PR interval : value >280 msec | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| PR interval : %change>=25/50% | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 |
| QRS interval: value >120 msec | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| QRS interval: %Change>=50% | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| QTCF: 450 msec | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| QTCF: 30<=Change<60 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 |
| Units per liter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Change at week 1 | 0.4 ± 25.99 | -7.4 ± 30.20 | -5.3 ± 16.99 | -9.3 ± 22.65 | -18.4 ± 33.42 | -8.0 ± 34.51 | -8.0 ± 19.37 | -4.3 ± 29.08 |
| Change at week 2 | -8.8 ± 21.56 | -7.8 ± 27.99 | -1.9 ± 18.18 | -8.8 ± 23.70 | -15.8 ± 42.19 | -0.3 ± 22.81 | -8.0 ± 22.31 | -4.9 ± 24.49 |
| Change at week 4 | -8.6 ± 23.93 | -5.4 ± 22.87 | -9.3 ± 19.61 | -12.1 ± 28.54 | -16.3 ± 33.97 | -1.0 ± 29.29 | -19.5 ± 19.94 | -3.7 ± 24.96 |
| Change at week 6 | -8.8 ± 18.25 | -8.1 ± 32.02 | -1.5 ± 32.42 | -6.4 ± 28.53 | -18.2 ± 33.86 | -9.7 ± 20.68 | -11.2 ± 22.34 | -7.0 ± 24.65 |
| Change at follow-up visit | -12.3 ± 24.82 | -12.0 ± 28.83 | 4.0 ± 43.45 | -2.7 ± 26.27 | -15.1 ± 38.23 | -11.3 ± 29.39 | -13.3 ± 25.37 | 0.2 ± 16.48 |
| Gram per deciliter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Protein: change at week 1 | -0.01 ± 0.439 | -0.04 ± 0.294 | -0.14 ± 0.433 | -0.04 ± 0.264 | -0.03 ± 0.421 | -0.10 ± 0.360 | -0.01 ± 0.344 | -0.02 ± 0.301 |
| Protein:change at week 2 | -0.09 ± 0.383 | 0.03 ± 0.303 | -0.18 ± 0.402 | -0.01 ± 0.275 | 0.01 ± 0.561 | 0.02 ± 0.503 | -0.04 ± 0.286 | -0.10 ± 0.299 |
| Protein: change at week 4 | -0.10 ± 0.380 | 0.07 ± 0.315 | -0.08 ± 0.429 | -0.03 ± 0.341 | -0.04 ± 0.465 | -0.18 ± 0.292 | -0.15 ± 0.242 | 0.03 ± 0.280 |
| Protein: change at week 6 | -0.13 ± 0.403 | 0.13 ± 0.379 | -0.19 ± 0.452 | 0.01 ± 0.368 | -0.03 ± 0.405 | -0.10 ± 0.424 | -0.09 ± 0.368 | -0.09 ± 0.310 |
| Protein: change at follow-up visit | -0.07 ± 0.341 | 0.05 ± 0.457 | -0.15 ± 0.481 | -0.04 ± 0.404 | 0.03 ± 0.481 | -0.18 ± 0.471 | -0.09 ± 0.398 | 0.02 ± 0.299 |
| Albumin:change at week 1 | -0.04 ± 0.269 | -0.05 ± 0.205 | -0.10 ± 0.283 | -0.02 ± 0.177 | 0.00 ± 0.256 | -0.05 ± 0.218 | -0.03 ± 0.246 | 0.00 ± 0.169 |
| Albumin:change at week 2 | -0.06 ± 0.235 | 0.02 ± 0.201 | -0.10 ± 0.256 | -0.02 ± 0.204 | -0.01 ± 0.283 | 0.02 ± 0.266 | -0.03 ± 0.174 | -0.06 ± 0.202 |
| Albumin: change at week 4 | -0.08 ± 0.245 | 0.07 ± 0.172 | -0.08 ± 0.285 | 0.01 ± 0.239 | 0.04 ± 0.292 | -0.10 ± 0.232 | -0.08 ± 0.180 | 0.03 ± 0.224 |
| Albumin:change at week 6 | -0.08 ± 0.259 | 0.08 ± 0.245 | -0.14 ± 0.333 | -0.02 ± 0.269 | -0.00 ± 0.218 | -0.03 ± 0.252 | -0.07 ± 0.244 | -0.05 ± 0.227 |
| Albumin: change at follow-up visit | -0.06 ± 0.247 | 0.10 ± 0.260 | -0.09 ± 0.277 | -0.04 ± 0.295 | -0.01 ± 0.346 | -0.09 ± 0.262 | -0.02 ± 0.211 | 0.06 ± 0.181 |
| Microgram per deciliter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Urea nitrogen: change at week 1 | 0.9 ± 4.57 | 0.6 ± 3.04 | 0.1 ± 3.12 | 1.0 ± 3.19 | 1.0 ± 3.05 | 0.2 ± 2.19 | 0.4 ± 3.38 | -0.1 ± 2.65 |
| Urea nitrogen: change at week 2 | 0.8 ± 3.89 | 0.0 ± 2.71 | 0.6 ± 3.54 | 0.9 ± 3.18 | 0.5 ± 3.63 | 0.6 ± 4.19 | 0.8 ± 2.99 | 0.4 ± 3.28 |
| Urea nitrogen: change at week 4 | 0.6 ± 3.39 | 0.0 ± 3.04 | -0.0 ± 2.67 | 1.4 ± 3.06 | 0.5 ± 3.84 | -0.7 ± 2.96 | 1.3 ± 2.81 | -0.2 ± 3.61 |
| Urea nitrogen: change at week 6 | 0.7 ± 2.84 | -0.2 ± 3.11 | -0.6 ± 3.61 | 0.9 ± 3.27 | 0.3 ± 3.82 | -0.8 ± 3.24 | 0.2 ± 3.52 | -0.4 ± 3.69 |
| Urea nitrogen: change at follow-up visit | 0.0 ± 3.17 | -0.3 ± 3.13 | 0.4 ± 2.60 | 1.2 ± 4.22 | 0.2 ± 2.87 | 0.8 ± 3.78 | 0.5 ± 3.42 | 0.1 ± 3.78 |
| Urate:change at week 1 | 0.16 ± 0.807 | 0.01 ± 0.606 | 0.16 ± 0.678 | -0.01 ± 0.561 | 0.00 ± 0.739 | 0.05 ± 0.661 | -0.02 ± 0.704 | -0.14 ± 0.890 |
| Urate: change at week 2 | 0.30 ± 0.990 | -0.11 ± 0.655 | 0.12 ± 0.617 | -0.03 ± 0.649 | -0.15 ± 0.842 | 0.27 ± 1.025 | -0.03 ± 0.718 | -0.37 ± 1.059 |
| Urate: change at week 4 | 0.21 ± 0.497 | 0.14 ± 0.731 | 0.06 ± 0.756 | -0.06 ± 0.621 | -0.14 ± 0.856 | 0.22 ± 0.806 | -0.21 ± 0.663 | -0.16 ± 0.713 |
| Urate: change at week 6 | 0.13 ± 0.728 | 0.07 ± 0.984 | -0.02 ± 0.831 | 0.06 ± 0.630 | -0.02 ± 0.649 | 0.06 ± 0.534 | -0.11 ± 0.827 | -0.21 ± 1.084 |
| Urate: change at follow- up visit | -0.11 ± 0.721 | -0.33 ± 0.753 | 0.05 ± 0.763 | -0.21 ± 0.554 | -0.02 ± 0.810 | 0.02 ± 0.590 | -0.08 ± 0.677 | -0.20 ± 0.989 |
| Calcium:change at week 1 | 0.01 ± 0.419 | 0.01 ± 0.259 | -0.06 ± 0.377 | -0.02 ± 0.248 | 0.07 ± 0.386 | -0.02 ± 0.303 | -0.01 ± 0.295 | 0.09 ± 0.318 |
| Calcium: change at week 2 | -0.08 ± 0.417 | 0.00 ± 0.268 | -0.10 ± 0.362 | 0.05 ± 0.296 | 0.07 ± 0.423 | 0.03 ± 0.389 | -0.10 ± 0.293 | -0.01 ± 0.244 |
| Calcium: change at week 4 | -0.04 ± 0.354 | 0.11 ± 0.329 | -0.07 ± 0.345 | 0.05 ± 0.272 | 0.00 ± 0.376 | -0.08 ± 0.309 | -0.03 ± 0.257 | 0.10 ± 0.341 |
| Calcium: change at week 6 | -0.04 ± 0.355 | 0.10 ± 0.303 | -0.21 ± 0.393 | 0.03 ± 0.315 | 0.00 ± 0.397 | -0.05 ± 0.335 | -0.05 ± 0.464 | -0.04 ± 0.337 |
| Calcium: change at follow-up visit | 0.00 ± 0.317 | -0.01 ± 0.345 | -0.08 ± 0.409 | 0.00 ± 0.323 | 0.10 ± 0.441 | -0.05 ± 0.419 | 0.01 ± 0.378 | 0.05 ± 0.356 |
| Glucose:change at week 1 | 4.9 ± 8.73 | 5.7 ± 13.97 | 3.4 ± 14.62 | 4.5 ± 8.60 | 4.4 ± 16.14 | 4.5 ± 29.90 | 5.6 ± 13.14 | 3.3 ± 13.58 |
| Glucose: change at week 2 | 9.7 ± 23.71 | 1.2 ± 17.34 | 0.6 ± 10.97 | 3.2 ± 12.63 | 3.1 ± 10.00 | -1.9 ± 13.51 | 7.9 ± 16.67 | 2.7 ± 18.07 |
| Glucose: change at week 4 | 7.3 ± 15.60 | 0.5 ± 12.50 | -1.2 ± 15.86 | 4.5 ± 13.99 | 2.8 ± 20.20 | 1.3 ± 24.01 | 10.7 ± 26.13 | 3.4 ± 18.33 |
| Glucose: change at week 6 | 3.5 ± 9.19 | 2.4 ± 17.55 | -1.7 ± 10.62 | 2.1 ± 13.80 | -0.5 ± 9.77 | -3.4 ± 16.37 | 4.3 ± 12.23 | 1.5 ± 12.62 |
| Glucose: change at follow -up visit | 4.5 ± 11.58 | 2.2 ± 11.45 | 4.8 ± 13.28 | 4.6 ± 14.77 | 6.0 ± 13.79 | 6.2 ± 16.75 | 9.1 ± 17.21 | 2.0 ± 22.43 |
| Milliequivalents per liter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Sodium: change at week 1 | 0.1 ± 2.34 | -0.0 ± 1.77 | -0.7 ± 2.04 | -0.6 ± 2.17 | -0.4 ± 3.50 | 0.4 ± 1.97 | 0.0 ± 2.08 | -0.1 ± 3.39 |
| Sodium: change at week 2 | -0.5 ± 2.23 | -0.3 ± 1.89 | -0.1 ± 2.39 | -0.2 ± 2.18 | -0.4 ± 3.61 | -0.2 ± 2.61 | -0.5 ± 2.20 | -0.3 ± 3.45 |
| Sodium:change at week 4 | -0.3 ± 2.70 | 0.6 ± 1.83 | -0.2 ± 2.44 | -0.7 ± 2.71 | -0.4 ± 3.08 | -0.4 ± 2.72 | -0.1 ± 1.77 | -0.3 ± 3.28 |
| Sodium:change at week 6 | -0.8 ± 2.31 | 0.0 ± 2.39 | -0.2 ± 2.23 | -0.9 ± 2.40 | -0.9 ± 3.55 | 0.9 ± 2.50 | -0.1 ± 2.23 | -0.5 ± 2.49 |
| Sodium: change at follow up | -0.4 ± 3.26 | 0.5 ± 2.50 | -0.1 ± 2.45 | -0.3 ± 2.41 | -0.8 ± 3.59 | 0.7 ± 1.94 | -0.1 ± 2.46 | 0.1 ± 3.32 |
| Potassium: change at week 1 | -0.00 ± 0.363 | 0.08 ± 0.282 | 0.03 ± 0.372 | 0.02 ± 0.347 | 0.07 ± 0.343 | 0.01 ± 0.337 | 0.00 ± 0.429 | 0.20 ± 0.464 |
| Potassium:change at week 2 | -0.14 ± 0.367 | 0.04 ± 0.298 | -0.07 ± 0.338 | 0.04 ± 0.359 | 0.07 ± 0.346 | 0.00 ± 0.245 | -0.16 ± 0.438 | -0.02 ± 0.322 |
| Potassium: change at week 4 | 0.01 ± 0.389 | -0.06 ± 0.285 | -0.02 ± 0.350 | -0.01 ± 0.327 | 0.05 ± 0.375 | -0.09 ± 0.300 | -0.03 ± 0.415 | 0.26 ± 0.350 |
| Potassium: change at week 6 | -0.09 ± 0.373 | 0.03 ± 0.295 | -0.06 ± 0.332 | 0.03 ± 0.407 | -0.06 ± 0.262 | -0.06 ± 0.309 | -0.10 ± 0.355 | 0.09 ± 0.388 |
| Potassium: change at follow-up visit | -0.11 ± 0.379 | 0.10 ± 0.375 | 0.03 ± 0.394 | 0.04 ± 0.351 | 0.12 ± 0.358 | 0.05 ± 0.293 | -0.09 ± 0.475 | 0.26 ± 0.460 |
| Chloride: change at week 1 | 0.1 ± 2.11 | 0.3 ± 1.86 | 0.3 ± 1.57 | 0.0 ± 2.54 | 0.0 ± 2.66 | 0.6 ± 2.11 | 0.5 ± 2.02 | 0.5 ± 2.83 |
| Chloride: change at week 2 | -0.2 ± 2.52 | -0.2 ± 2.08 | 0.7 ± 2.03 | 0.2 ± 2.50 | -0.2 ± 2.87 | 0.4 ± 2.70 | 0.4 ± 2.15 | 0.2 ± 2.99 |
| Chloride: change at week 4 | 0.3 ± 2.05 | 0.6 ± 1.89 | 0.2 ± 2.68 | -0.4 ± 2.23 | -0.3 ± 2.16 | 0.3 ± 3.28 | 1.0 ± 2.21 | -0.2 ± 2.57 |
| Chloride:change at week 6 | -0.6 ± 1.98 | 0.1 ± 2.27 | 0.0 ± 2.34 | -0.5 ± 2.44 | -0.4 ± 3.05 | 0.5 ± 2.93 | 0.9 ± 2.73 | 0.0 ± 2.32 |
| Chloride: change at follow-up visit | 0.6 ± 2.97 | -0.3 ± 2.16 | 0.8 ± 2.64 | 0.1 ± 2.41 | -0.4 ± 2.90 | 1.3 ± 2.11 | 0.3 ± 2.35 | 0.4 ± 3.16 |
| Bicarbonate: change at week 1 | 0.13 ± 2.548 | -0.38 ± 1.759 | -0.20 ± 1.965 | -0.18 ± 1.768 | 0.28 ± 1.638 | 0.09 ± 2.209 | -0.21 ± 2.388 | -0.02 ± 1.651 |
| Bicarbonate: change at week 2 | 0.08 ± 2.229 | -0.40 ± 2.151 | -0.51 ± 1.956 | 0.10 ± 2.129 | -0.13 ± 1.931 | -0.15 ± 2.341 | -0.60 ± 2.354 | -0.07 ± 1.828 |
| Bicarbonate: change at week 4 | 0.21 ± 2.739 | 0.05 ± 2.128 | -0.24 ± 2.484 | 0.34 ± 1.868 | 0.02 ± 2.011 | 0.14 ± 1.286 | -0.00 ± 2.695 | 0.02 ± 1.704 |
| Bicarbonate: change at week 6 | 0.52 ± 2.560 | -0.44 ± 2.598 | 0.66 ± 2.132 | 0.27 ± 2.204 | 0.12 ± 2.407 | 0.63 ± 2.096 | -0.19 ± 2.038 | -0.20 ± 2.217 |
| Bicarbonate: change at follow-up visit | -0.02 ± 2.916 | 0.66 ± 2.209 | 0.41 ± 2.056 | 0.75 ± 2.386 | 0.43 ± 2.162 | 0.08 ± 1.643 | 0.18 ± 2.300 | 1.09 ± 2.049 |
| Gram per deciliter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Change at week 1 | -0.01 ± 0.790 | -0.22 ± 0.620 | -0.36 ± 0.775 | -0.12 ± 0.678 | -0.26 ± 0.726 | -0.19 ± 0.698 | -0.21 ± 0.584 | -0.27 ± 0.679 |
| Change at week 2 | -0.16 ± 0.636 | -0.09 ± 0.566 | -0.64 ± 0.715 | -0.24 ± 0.657 | -0.22 ± 0.798 | -0.16 ± 0.830 | -0.25 ± 0.625 | -0.32 ± 0.793 |
| Change at week 4 | 0.03 ± 0.725 | -0.17 ± 0.630 | -0.48 ± 0.659 | -0.25 ± 0.628 | -0.06 ± 0.821 | -0.27 ± 0.789 | -0.32 ± 0.701 | -0.20 ± 0.658 |
| Change at week 6 | -0.13 ± 0.832 | -0.06 ± 0.614 | -0.48 ± 0.767 | -0.03 ± 0.617 | -0.11 ± 0.775 | -0.22 ± 0.724 | -0.21 ± 0.833 | -0.28 ± 0.683 |
| Change at follow-up visit | 0.05 ± 0.613 | -0.04 ± 0.717 | -0.49 ± 0.777 | -0.09 ± 0.784 | 0.00 ± 0.773 | -0.27 ± 0.756 | -0.12 ± 0.826 | -0.18 ± 0.740 |
| Percentage of cells | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Hematocrit: change at week 1 | 0.2 ± 2.51 | -0.8 ± 2.11 | -1.3 ± 2.61 | -0.4 ± 2.27 | -0.8 ± 2.41 | -0.5 ± 1.97 | -0.9 ± 2.04 | -0.9 ± 2.30 |
| Hematocrit: change at week 2 | -0.5 ± 2.19 | -0.8 ± 2.12 | -1.8 ± 2.42 | -0.9 ± 2.32 | -0.7 ± 2.58 | -0.9 ± 2.55 | -0.7 ± 2.24 | -1.0 ± 2.61 |
| Hematocrit: change at week 4 | 0.0 ± 2.45 | -0.8 ± 1.96 | -1.8 ± 2.06 | -0.8 ± 2.34 | 0.0 ± 2.73 | -1.0 ± 2.34 | -0.9 ± 2.29 | -0.5 ± 2.56 |
| Hematocrit: change at week 6 | -0.6 ± 2.47 | -0.9 ± 1.93 | -1.6 ± 2.64 | -0.7 ± 2.23 | -0.6 ± 2.51 | -1.1 ± 1.98 | -1.1 ± 2.84 | -0.8 ± 2.60 |
| Hematocrit: change at follow-up (FU) visit | 0.3 ± 2.49 | -0.7 ± 2.24 | -1.4 ± 3.05 | -0.7 ± 2.39 | -0.2 ± 2.50 | -0.6 ± 2.20 | -0.6 ± 2.73 | -0.3 ± 2.78 |
| Reticulocytes/Erythrocytes change at week 1 | 0.03 ± 0.317 | 0.14 ± 0.378 | 0.02 ± 0.483 | 0.06 ± 0.364 | 0.11 ± 0.318 | 0.01 ± 0.320 | 0.04 ± 0.355 | 0.01 ± 0.329 |
| Reticulocytes/Erythrocytes: change at week 2 | -0.03 ± 0.382 | 0.17 ± 0.325 | 0.09 ± 0.413 | -0.02 ± 0.473 | 0.19 ± 0.443 | -0.10 ± 0.318 | 0.06 ± 0.315 | -0.01 ± 0.389 |
| Reticulocytes/Erythrocytes: change at week 4 | 0.16 ± 0.596 | -0.08 ± 0.359 | 0.01 ± 0.460 | 0.19 ± 0.429 | 0.10 ± 0.409 | 0.03 ± 0.290 | 0.04 ± 0.446 | 0.05 ± 0.374 |
| Reticulocytes/Erythrocytes: change at week 6 | -0.06 ± 0.382 | 0.02 ± 0.361 | 0.02 ± 0.473 | 0.01 ± 0.486 | 0.15 ± 0.399 | -0.15 ± 0.310 | -0.01 ± 0.355 | 0.01 ± 0.463 |
| Reticulocytes/Erythrocytes:change at FU visit | -0.11 ± 0.396 | -0.02 ± 0.384 | 0.10 ± 0.435 | -0.10 ± 0.398 | -0.03 ± 0.298 | -0.09 ± 0.331 | -0.19 ± 0.395 | 0.11 ± 0.448 |
| Lymphocytes/Leukocytes: change at week 1 | -0.43 ± 6.772 | 0.68 ± 5.814 | 2.33 ± 5.616 | 0.06 ± 4.765 | 1.31 ± 6.259 | 0.59 ± 5.179 | 0.49 ± 5.509 | 1.79 ± 6.269 |
| Lymphocytes/Leukocytes: change at week 2 | 0.20 ± 6.175 | 0.84 ± 7.544 | 1.68 ± 5.208 | 1.50 ± 5.639 | 0.23 ± 6.175 | 0.50 ± 5.405 | 0.72 ± 6.638 | 0.86 ± 7.264 |
| Lymphocytes/Leukocytes: change at week 4 | 1.58 ± 7.591 | 0.51 ± 7.297 | 1.43 ± 5.298 | 0.43 ± 7.586 | 2.41 ± 6.577 | -1.38 ± 5.415 | 1.07 ± 5.739 | 0.56 ± 7.264 |
| Lymphocytes/Leukocytes: change at week 6 | -0.92 ± 6.701 | -0.06 ± 5.461 | 0.82 ± 6.685 | 1.28 ± 5.881 | 1.65 ± 5.818 | 0.50 ± 4.452 | -0.04 ± 5.300 | 1.52 ± 7.266 |
| Lymphocytes/Leukocytes: change at follow-up visit | 1.53 ± 6.219 | 1.25 ± 4.974 | 1.61 ± 6.597 | -0.85 ± 6.367 | 1.34 ± 6.165 | 0.22 ± 6.315 | 0.07 ± 5.103 | 2.48 ± 6.914 |
| Neutrophils/Leukocytes: change at week 1 | 0.57 ± 7.515 | -0.95 ± 6.957 | -2.93 ± 6.191 | 0.30 ± 5.755 | -0.96 ± 7.843 | -0.17 ± 5.769 | -1.87 ± 6.873 | -1.44 ± 6.580 |
| Neutrophils/Leukocytes: change at week 2 | -0.12 ± 7.827 | -0.34 ± 8.219 | -1.70 ± 6.037 | -1.50 ± 6.578 | -0.24 ± 6.146 | -0.49 ± 6.665 | -1.04 ± 7.376 | -0.56 ± 8.017 |
| Neutrophils/Leukocytes: change at week 4 | -1.42 ± 8.812 | -0.30 ± 7.754 | -1.52 ± 6.661 | 0.06 ± 8.536 | -2.25 ± 7.468 | 1.65 ± 6.622 | -1.42 ± 6.498 | -0.45 ± 7.362 |
| Neutrophils/Leukocytes: change at week 6 | 0.95 ± 8.648 | -0.58 ± 7.009 | -0.64 ± 6.833 | -1.14 ± 6.872 | -1.15 ± 6.969 | -0.56 ± 5.699 | 0.13 ± 6.029 | -1.01 ± 8.445 |
| Neutrophils/Leukocytes: change at follow-up visit | -1.71 ± 7.046 | -0.65 ± 6.057 | -1.86 ± 6.892 | 1.32 ± 7.355 | -1.32 ± 6.559 | -0.41 ± 6.961 | -0.71 ± 6.590 | -2.04 ± 7.700 |
| Basophils/Leukocytes: change at week 1 | -0.06 ± 0.431 | -0.02 ± 0.690 | -0.06 ± 0.524 | 0.08 ± 0.319 | 0.03 ± 0.515 | -0.03 ± 0.291 | -0.01 ± 0.411 | -0.01 ± 0.570 |
| Basophils/Leukocytes: change at week 2 | -0.02 ± 0.304 | 0.01 ± 0.493 | -0.09 ± 0.342 | 0.02 ± 0.323 | -0.03 ± 0.532 | 0.03 ± 0.355 | -0.06 ± 0.624 | -0.24 ± 0.709 |
| Basophils/Leukocytes: change at week 4 | -0.07 ± 0.485 | 0.06 ± 0.651 | -0.03 ± 0.420 | 0.01 ± 0.402 | -0.08 ± 0.712 | -0.05 ± 0.362 | -0.01 ± 0.465 | -0.10 ± 0.464 |
| Basophils/Leukocytes: change at week 6 | -0.07 ± 0.272 | 0.11 ± 0.809 | -0.12 ± 0.480 | 0.08 ± 0.458 | -0.16 ± 0.557 | -0.05 ± 0.296 | -0.12 ± 0.576 | -0.17 ± 0.750 |
| Basophils/Leukocytes: change at follow-up visit | -0.04 ± 0.360 | -0.15 ± 0.476 | -0.13 ± 0.443 | 0.02 ± 0.512 | -0.25 ± 0.541 | -0.05 ± 0.449 | 0.01 ± 0.472 | -0.25 ± 0.572 |
| Eosinophils/Leukocytes: change at week 1 | -0.09 ± 1.390 | 0.17 ± 1.840 | 0.17 ± 0.934 | -0.37 ± 1.549 | -0.31 ± 1.607 | -0.19 ± 1.410 | 0.89 ± 1.850 | -0.23 ± 1.339 |
| Eosinophils/Leukocytes: change at week 2 | -0.11 ± 1.801 | -0.20 ± 1.298 | -0.16 ± 1.284 | 0.11 ± 1.460 | -0.27 ± 1.131 | -0.14 ± 1.199 | 0.16 ± 1.304 | -0.05 ± 1.531 |
| Eosinophils/Leukocytes: change at week 4 | 0.42 ± 1.982 | -0.12 ± 1.725 | 0.15 ± 1.884 | -0.37 ± 1.729 | -0.35 ± 1.431 | -0.34 ± 1.258 | 0.40 ± 1.468 | -0.37 ± 1.747 |
| Eosinophils/Leukocytes: change at week 6 | -0.03 ± 1.522 | 0.22 ± 1.570 | -0.04 ± 1.213 | 0.02 ± 2.126 | -0.15 ± 1.714 | -0.01 ± 1.767 | 0.05 ± 1.229 | -0.19 ± 1.840 |
| Eosinophils/Leukocytes: change at follow-up visit | 0.16 ± 1.754 | -0.24 ± 1.860 | -0.09 ± 1.155 | -0.41 ± 2.188 | 0.12 ± 1.954 | -0.05 ± 2.805 | 0.50 ± 1.986 | -0.13 ± 2.021 |
| Monocytes/Leukocytes: change at week 1 | 0.02 ± 1.913 | 0.12 ± 1.391 | 0.50 ± 1.428 | -0.06 ± 1.409 | -0.01 ± 1.593 | -0.19 ± 1.043 | 0.51 ± 1.275 | -0.11 ± 1.251 |
| Monocytes/Leukocytes: change at week 2 | 0.04 ± 2.055 | -0.31 ± 1.502 | 0.30 ± 1.522 | -0.13 ± 1.267 | 0.38 ± 1.362 | 0.11 ± 1.318 | 0.22 ± 1.414 | -0.01 ± 1.755 |
| Monocytes/Leukocytes : change at week 4 | -0.51 ± 2.509 | -0.17 ± 1.966 | -0.02 ± 2.072 | -0.10 ± 1.582 | 0.22 ± 1.323 | 0.14 ± 1.323 | -0.03 ± 1.039 | 0.33 ± 1.695 |
| Monocytes/Leukocytes : change at week 6 | 0.06 ± 2.488 | 0.33 ± 2.257 | -0.00 ± 1.813 | -0.24 ± 1.217 | -0.12 ± 1.030 | 0.13 ± 0.807 | -0.02 ± 1.324 | -0.16 ± 1.516 |
| Monocytes/Leukocytes : change at follow-up visit | 0.06 ± 2.105 | -0.22 ± 1.304 | 0.50 ± 1.463 | -0.07 ± 1.226 | 0.13 ± 1.205 | 0.26 ± 1.543 | 0.15 ± 1.599 | -0.04 ± 1.047 |
| 10^12*cells per liter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Erythrocytes: change at week 1 | 0.03 ± 0.261 | -0.07 ± 0.232 | -0.12 ± 0.264 | -0.04 ± 0.252 | -0.08 ± 0.254 | -0.08 ± 0.298 | -0.08 ± 0.192 | -0.09 ± 0.240 |
| Erythrocytes: change at week 2 | -0.05 ± 0.234 | -0.03 ± 0.212 | -0.18 ± 0.251 | -0.10 ± 0.208 | -0.07 ± 0.242 | -0.10 ± 0.366 | -0.06 ± 0.229 | -0.11 ± 0.232 |
| Erythrocytes: change at week 4 | -0.01 ± 0.216 | -0.05 ± 0.221 | -0.16 ± 0.251 | -0.10 ± 0.233 | 0.01 ± 0.275 | -0.12 ± 0.271 | -0.08 ± 0.248 | -0.06 ± 0.219 |
| Erythrocytes: change at week 6 | -0.04 ± 0.247 | -0.01 ± 0.180 | -0.17 ± 0.265 | -0.04 ± 0.238 | -0.02 ± 0.262 | -0.10 ± 0.256 | -0.07 ± 0.303 | -0.08 ± 0.239 |
| Erythrocytes: change at follow-up visit | 0.03 ± 0.220 | 0.02 ± 0.244 | -0.15 ± 0.266 | -0.03 ± 0.254 | 0.04 ± 0.300 | -0.08 ± 0.280 | -0.03 ± 0.308 | -0.05 ± 0.262 |
| Reticulocytes: change at week 1 | 0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | 0.0 ± 0.02 | 0.0 ± 0.01 | 0.0 ± 0.02 | -0.0 ± 0.02 |
| Reticulocytes: change at week 2 | -0.0 ± 0.02 | 0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 |
| Reticulocytes: change at week 4 | 0.0 ± 0.03 | -0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.01 | -0.0 ± 0.02 | 0.0 ± 0.02 |
| Reticulocytes: change at week 6 | -0.0 ± 0.02 | 0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.01 | -0.0 ± 0.02 | 0.0 ± 0.02 |
| Reticulocytes: change at follow-up visit | -0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 | -0.0 ± 0.02 | -0.0 ± 0.01 | -0.0 ± 0.02 | -0.0 ± 0.02 | 0.0 ± 0.02 |
| 10^9 *cells per liter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Platelets: change at week 1 | 0.9 ± 60.03 | 6.8 ± 34.08 | -3.3 ± 32.39 | 1.0 ± 25.76 | 8.5 ± 41.61 | 6.6 ± 33.40 | -2.1 ± 31.94 | 12.6 ± 44.08 |
| Platelets: change at week 2 | -4.9 ± 58.16 | 7.1 ± 43.34 | -8.1 ± 41.92 | -0.1 ± 32.45 | 5.0 ± 31.39 | -4.9 ± 31.84 | 7.5 ± 37.94 | 14.8 ± 50.99 |
| Platelets: change at week 4 | 10.5 ± 36.42 | 10.1 ± 37.55 | -2.4 ± 37.68 | -0.3 ± 36.27 | -5.9 ± 37.47 | 4.4 ± 37.79 | 0.7 ± 36.51 | 11.0 ± 46.26 |
| Platelets: change at week 6 | 4.9 ± 35.17 | -3.3 ± 32.76 | -6.6 ± 41.66 | -2.3 ± 32.70 | -5.2 ± 38.53 | 0.2 ± 37.28 | -1.8 ± 37.05 | 8.6 ± 47.85 |
| Platelets: change at follow-up visit | 1.3 ± 30.48 | 16.3 ± 37.13 | -8.5 ± 30.15 | 0.1 ± 32.36 | 10.2 ± 47.30 | -5.2 ± 40.70 | 5.8 ± 48.55 | 2.5 ± 58.75 |
| Leukocytes: change at week 1 | 0.027 ± 1.8740 | 0.395 ± 1.0940 | -0.051 ± 1.2403 | 0.407 ± 1.2225 | 0.259 ± 1.1290 | 0.068 ± 1.2929 | 0.238 ± 1.4993 | -0.025 ± 2.3529 |
| Leukocytes: change at week 2 | -0.206 ± 1.8886 | 0.459 ± 1.5567 | -0.288 ± 1.6842 | -0.094 ± 1.2877 | -0.116 ± 1.0364 | -0.007 ± 1.2637 | 0.422 ± 1.8986 | -0.006 ± 2.3428 |
| Leukocytes: change at week 4 | -0.203 ± 1.7390 | 0.729 ± 1.3199 | 0.189 ± 1.3534 | 0.085 ± 1.3541 | -0.074 ± 1.0641 | 0.398 ± 1.5999 | 0.168 ± 1.0902 | 0.041 ± 2.1647 |
| Leukocytes: change at week 6 | 0.160 ± 1.7059 | 0.066 ± 1.0672 | -0.505 ± 1.6474 | 0.237 ± 1.4501 | -0.244 ± 1.2763 | -0.269 ± 1.0761 | -0.048 ± 1.3823 | -0.347 ± 2.1442 |
| Leukocytes: change at follow-up visit | -0.066 ± 1.5744 | 0.479 ± 1.0939 | -0.048 ± 2.0206 | 0.329 ± 1.3938 | 0.123 ± 0.8496 | -0.117 ± 1.4856 | 0.210 ± 1.7456 | -0.404 ± 2.4817 |
| Lymphocytes: change at week 1 | -0.008 ± 0.5539 | 0.124 ± 0.3659 | 0.107 ± 0.3130 | 0.081 ± 0.3839 | 0.186 ± 0.3840 | 0.051 ± 0.3557 | 0.089 ± 0.4320 | 0.223 ± 0.3849 |
| Lymphocytes: change at week 2 | -0.061 ± 0.5558 | 0.145 ± 0.3735 | 0.010 ± 0.4115 | 0.044 ± 0.4225 | 0.012 ± 0.4251 | -0.003 ± 0.3165 | 0.070 ± 0.4603 | 0.169 ± 0.5319 |
| Lymphocytes: change at week 4 | 0.107 ± 0.4302 | 0.229 ± 0.3998 | 0.135 ± 0.4400 | 0.012 ± 0.4596 | 0.139 ± 0.3977 | 0.039 ± 0.4169 | 0.127 ± 0.2630 | 0.176 ± 0.6274 |
| Lymphocytes: change at week 6 | 0.033 ± 0.3375 | 0.016 ± 0.3437 | -0.079 ± 0.4826 | 0.104 ± 0.4337 | 0.068 ± 0.3168 | -0.033 ± 0.3092 | 0.027 ± 0.2455 | 0.079 ± 0.3846 |
| Lymphocytes: change at follow-up visit | 0.134 ± 0.3256 | 0.194 ± 0.3533 | 0.065 ± 0.6042 | -0.022 ± 0.4419 | 0.130 ± 0.4277 | -0.035 ± 0.4054 | 0.050 ± 0.4699 | 0.195 ± 0.4663 |
| Neutrophils: change at week 1 | 0.027 ± 1.6137 | 0.205 ± 0.9185 | -0.177 ± 1.0805 | 0.319 ± 1.0276 | 0.069 ± 1.0706 | 0.017 ± 1.1291 | 0.030 ± 1.3015 | -0.251 ± 2.2421 |
| Neutrophils: change at week 2 | -0.119 ± 1.5672 | 0.293 ± 1.5459 | -0.261 ± 1.3969 | -0.136 ± 1.0669 | -0.109 ± 0.9653 | -0.015 ± 1.1305 | 0.288 ± 1.7822 | -0.190 ± 2.0749 |
| Neutrophils: change at week 4 | -0.304 ± 1.6117 | 0.441 ± 1.2814 | 0.036 ± 1.1595 | 0.096 ± 1.3199 | -0.190 ± 1.0404 | 0.338 ± 1.3577 | -0.005 ± 0.9958 | -0.158 ± 2.0005 |
| Neutrophils: change at week 6 | 0.112 ± 1.6282 | -0.001 ± 0.8996 | -0.362 ± 1.3154 | 0.112 ± 1.2240 | -0.250 ± 1.1720 | -0.228 ± 0.9681 | -0.064 ± 1.2422 | -0.376 ± 2.1125 |
| Neutrophils: change at follow-up visit | -0.229 ± 1.3379 | 0.261 ± 0.8874 | -0.114 ± 1.4545 | 0.343 ± 1.3049 | -0.020 ± 0.7731 | -0.093 ± 1.2340 | 0.088 ± 1.4614 | -0.562 ± 2.3227 |
| Basophils: change at week 1 | -0.006 ± 0.0319 | 0.004 ± 0.0445 | -0.007 ± 0.0349 | 0.010 ± 0.0258 | 0.003 ± 0.0361 | 0.001 ± 0.0191 | 0.002 ± 0.0299 | 0.002 ± 0.0343 |
| Basophils: change at week 2 | -0.002 ± 0.0179 | 0.004 ± 0.0261 | -0.009 ± 0.0276 | 0.001 ± 0.0197 | -0.005 ± 0.0394 | 0.003 ± 0.0244 | -0.003 ± 0.0433 | -0.012 ± 0.0428 |
| Basophils: change at week 4 | -0.006 ± 0.0328 | 0.011 ± 0.0404 | -0.002 ± 0.0300 | 0.001 ± 0.0256 | -0.007 ± 0.0495 | -0.001 ± 0.0255 | -0.001 ± 0.0337 | -0.004 ± 0.0323 |
| Basophils: change at week 6 | -0.005 ± 0.0186 | 0.009 ± 0.0489 | -0.012 ± 0.0313 | 0.008 ± 0.0344 | -0.015 ± 0.0415 | -0.004 ± 0.0188 | -0.009 ± 0.0373 | -0.015 ± 0.0383 |
| Basophils: change at follow-up visit | -0.004 ± 0.0265 | -0.003 ± 0.0259 | -0.007 ± 0.0321 | 0.007 ± 0.0407 | -0.015 ± 0.0426 | -0.005 ± 0.0269 | 0.001 ± 0.0295 | -0.019 ± 0.0361 |
| Eosinophils: change at week 1 | 0.007 ± 0.0964 | 0.036 ± 0.0963 | -0.004 ± 0.1092 | -0.011 ± 0.0930 | -0.014 ± 0.1216 | -0.008 ± 0.1148 | 0.068 ± 0.0959 | -0.006 ± 0.1165 |
| Eosinophils: change at week 2 | -0.019 ± 0.1087 | -0.000 ± 0.0734 | -0.023 ± 0.0809 | 0.009 ± 0.0980 | -0.029 ± 0.0915 | -0.006 ± 0.0621 | 0.022 ± 0.0762 | 0.005 ± 0.1256 |
| Eosinophils: change at week 4 | 0.032 ± 0.1813 | 0.018 ± 0.1120 | 0.008 ± 0.1325 | -0.019 ± 0.1102 | -0.032 ± 0.1040 | -0.012 ± 0.0832 | 0.042 ± 0.1076 | -0.012 ± 0.1499 |
| Eosinophils: change at week 6 | 0.002 ± 0.0935 | 0.029 ± 0.1090 | -0.025 ± 0.1351 | 0.018 ± 0.1387 | -0.027 ± 0.1125 | -0.007 ± 0.1025 | -0.001 ± 0.0812 | -0.022 ± 0.1415 |
| Eosinophils: change at follow-up visit | 0.022 ± 0.1461 | 0.006 ± 0.0931 | -0.023 ± 0.1196 | -0.004 ± 0.1810 | 0.008 ± 0.1270 | -0.008 ± 0.2483 | 0.048 ± 0.1520 | -0.011 ± 0.1945 |
| Monocytes: change at week 1 | 0.006 ± 0.1796 | 0.030 ± 0.0855 | 0.030 ± 0.0987 | 0.009 ± 0.0879 | 0.019 ± 0.1055 | 0.006 ± 0.0877 | 0.051 ± 0.1244 | 0.011 ± 0.1195 |
| Monocytes: change at week 2 | -0.006 ± 0.1509 | 0.016 ± 0.1343 | -0.003 ± 0.0724 | -0.014 ± 0.1055 | 0.017 ± 0.0865 | 0.013 ± 0.0983 | 0.049 ± 0.1471 | 0.025 ± 0.1496 |
| Monocytes: change at week 4 | -0.035 ± 0.1904 | 0.030 ± 0.1212 | 0.013 ± 0.1234 | -0.003 ± 0.1092 | 0.009 ± 0.0986 | 0.035 ± 0.0978 | 0.007 ± 0.1008 | 0.038 ± 0.1331 |
| Monocytes: change at week 6 | 0.017 ± 0.1777 | 0.017 ± 0.1069 | -0.025 ± 0.1191 | -0.005 ± 0.1021 | -0.019 ± 0.0726 | 0.004 ± 0.0847 | 0.003 ± 0.1097 | -0.012 ± 0.1200 |
| Monocytes: change at follow-up visit | 0.011 ± 0.1806 | 0.021 ± 0.0824 | 0.030 ± 0.1467 | 0.005 ± 0.0887 | 0.021 ± 0.0739 | 0.018 ± 0.1047 | 0.029 ± 0.1788 | -0.006 ± 0.1282 |
Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.
| Microgram per deciliter | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| HDL cholesterol | -2.8 ± 6.65 | 0.1 ± 5.34 | -1.3 ± 7.74 | 2.7 ± 8.33 | 1.9 ± 11.18 | 0.0 ± 6.76 | 1.2 ± 4.12 | 0.3 ± 8.56 |
| Triglycerides | 3.3 ± 38.84 | -4.2 ± 59.30 | -6.5 ± 37.30 | 1.8 ± 60.74 | -18.9 ± 56.78 | -8.1 ± 50.41 | -7.0 ± 58.36 | -4.4 ± 55.66 |
| Cholesterol | -3.5 ± 16.39 | -5.6 ± 27.59 | -12.8 ± 20.53 | 6.8 ± 24.09 | -10.4 ± 30.79 | -0.2 ± 18.70 | 5.3 ± 30.58 | -0.9 ± 19.86 |
| LDL Cholesterol | -3.4 ± 14.45 | -6.3 ± 25.28 | -12.1 ± 16.44 | 2.1 ± 20.13 | -11.0 ± 29.06 | -0.8 ± 14.48 | 4.4 ± 23.55 | -1.1 ± 16.29 |
Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.
| Ratio | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6 | 0.0 ± 0.31 | -0.1 ± 0.48 | -0.2 ± 0.40 | -0.0 ± 0.32 | -0.3 ± 0.77 | -0.0 ± 0.35 | 0.0 ± 0.46 | -0.0 ± 0.42 |
| Beats per minute | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Baseline | 66.8 ± 11.45 | 66.9 ± 9.33 | 68.4 ± 14.66 | 64.9 ± 9.05 | 64.9 ± 12.26 | 66.9 ± 12.03 | 68.2 ± 12.11 | 68.1 ± 12.48 |
| Change at week 2 | 0.7 ± 10.05 | -0.5 ± 8.03 | -1.8 ± 11.53 | -0.6 ± 7.88 | 1.9 ± 8.01 | 2.2 ± 8.76 | 1.7 ± 9.13 | 1.7 ± 12.52 |
| Change at week 6 | 0.3 ± 6.19 | -1.1 ± 7.65 | -1.7 ± 9.06 | 0.8 ± 8.53 | -0.3 ± 8.46 | -0.8 ± 8.23 | 0.5 ± 8.76 | -0.4 ± 12.06 |
| Milliseconds | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| PR interval: baseline | 161.9 ± 23.30 | 160.2 ± 24.01 | 161.4 ± 27.59 | 162.5 ± 22.04 | 160.7 ± 24.20 | 156.4 ± 22.65 | 157.9 ± 23.55 | 157.8 ± 23.15 |
| PR interval: change at week 2 | 0.8 ± 14.41 | -0.9 ± 15.92 | 0.7 ± 18.54 | 0.3 ± 10.13 | 1.1 ± 14.42 | 6.0 ± 14.79 | 1.2 ± 16.06 | 2.1 ± 7.98 |
| PR interval: change at week 6 | -0.9 ± 10.16 | -0.1 ± 13.81 | 2.8 ± 19.66 | 2.9 ± 13.63 | 3.5 ± 21.88 | 4.0 ± 14.56 | 6.5 ± 19.15 | 5.7 ± 16.11 |
| QRS interval: baseline | 92.5 ± 9.36 | 91.5 ± 9.71 | 91.1 ± 9.29 | 93.0 ± 11.13 | 93.1 ± 8.69 | 92.2 ± 13.00 | 92.4 ± 13.30 | 91.5 ± 11.68 |
| QRS interval: change at week 2 | -1.4 ± 8.02 | -0.4 ± 5.34 | -1.3 ± 3.46 | -0.8 ± 5.64 | 0.1 ± 4.79 | 1.5 ± 9.29 | 0.2 ± 8.07 | 1.0 ± 5.63 |
| QRS interval: change at week 6 | -1.9 ± 6.55 | 1.4 ± 5.62 | -0.5 ± 4.76 | -0.9 ± 4.04 | -1.3 ± 4.00 | 0.9 ± 6.37 | 0.6 ± 5.49 | 0.7 ± 5.67 |
| QTCF interval: baseline | 407.7 ± 17.78 | 397.9 ± 15.98 | 403.8 ± 22.43 | 408.5 ± 18.42 | 401.0 ± 16.29 | 403.0 ± 16.65 | 397.7 ± 17.05 | 405.0 ± 20.38 |
| QTCF interval: change at week 2 | -5.7 ± 11.86 | -1.5 ± 13.70 | -3.9 ± 15.60 | 2.6 ± 16.20 | -0.6 ± 12.75 | 1.4 ± 15.56 | 2.4 ± 10.32 | -4.6 ± 15.43 |
| QTCF interval: change at week 6 | -4.1 ± 14.61 | -0.5 ± 14.93 | -1.9 ± 14.37 | 0.3 ± 17.19 | -1.4 ± 14.93 | 4.6 ± 14.27 | 2.0 ± 11.94 | -0.2 ± 9.67 |
| QT interval: baseline | 395.2 ± 31.53 | 385.3 ± 23.64 | 388.8 ± 33.66 | 401.0 ± 25.23 | 392.0 ± 27.36 | 390.9 ± 24.87 | 383.8 ± 30.79 | 390.6 ± 32.43 |
| QT interval: change at week 2 | -5.9 ± 23.16 | -1.3 ± 17.73 | -1.1 ± 19.31 | 3.5 ± 21.06 | -4.5 ± 15.75 | 1.2 ± 24.03 | -2.3 ± 18.69 | -4.6 ± 25.76 |
| QT interval: change at week 6 | -4.9 ± 19.54 | 1.3 ± 18.11 | 0.9 ± 16.11 | -4.1 ± 23.42 | -0.9 ± 20.12 | 7.8 ± 24.11 | -1.4 ± 20.47 | 4.0 ± 27.74 |
Blood pressure included supine and sitting systolic and diastolic BP.
| Millimeters of mercury | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Supine systolic BP: Baseline | 123.3 ± 12.01 | 123.2 ± 12.35 | 123.0 ± 13.89 | 119.7 ± 9.08 | 122.6 ± 12.76 | 123.1 ± 12.40 | 117.1 ± 14.07 | 118.9 ± 12.43 |
| Supine systolic BP: change at week 2 | 0.3 ± 11.55 | -1.4 ± 9.61 | 0.5 ± 14.73 | 2.3 ± 6.99 | -0.3 ± 10.25 | -0.3 ± 8.02 | 3.5 ± 13.65 | 2.9 ± 8.48 |
| Supine systolic BP: change at week 6 | -0.2 ± 12.98 | 1.1 ± 10.06 | 2.0 ± 14.05 | 0.2 ± 9.13 | -3.4 ± 11.02 | -1.4 ± 10.49 | 2.1 ± 12.41 | 0.6 ± 10.31 |
| Sitting systolic BP: Baseline | 117.7 ± 13.05 | 120.8 ± 10.26 | 120.2 ± 12.43 | 116.9 ± 17.76 | 124.6 ± 11.25 | 119.4 ± 12.96 | 122.9 ± 15.25 | 125.6 ± 12.21 |
| Sitting systolic BP: change at week 2 | 1.3 ± 12.12 | -1.9 ± 11.86 | -3.9 ± 14.54 | 1.3 ± 13.59 | -2.4 ± 11.76 | -3.1 ± 10.46 | 1.1 ± 9.81 | 4.4 ± 11.68 |
| Sitting systolic BP: change at week 6 | 0.6 ± 12.24 | -7.5 ± 8.67 | -9.4 ± 8.95 | 1.0 ± 14.63 | -8.4 ± 10.81 | -0.6 ± 14.40 | -3.6 ± 8.37 | -1.5 ± 5.80 |
| Supine diastolic BP: Baseline | 77.7 ± 9.28 | 75.2 ± 8.79 | 78.8 ± 8.39 | 74.5 ± 8.26 | 75.9 ± 8.78 | 77.5 ± 8.71 | 74.4 ± 8.20 | 73.7 ± 8.59 |
| Supine diastolic BP: change at week 2 | 0.5 ± 7.51 | 0.6 ± 6.47 | -0.4 ± 8.50 | 1.6 ± 10.33 | 1.2 ± 8.32 | -2.8 ± 6.69 | 1.6 ± 8.89 | 1.4 ± 7.74 |
| Supine diastolic BP: change at week 6 | -2.5 ± 7.69 | 1.5 ± 7.61 | -0.7 ± 8.32 | 0.5 ± 7.96 | -0.9 ± 10.65 | -1.6 ± 6.22 | 1.9 ± 9.72 | 0.5 ± 6.32 |
| Sitting diastolic BP: Baseline | 76.5 ± 9.28 | 80.1 ± 6.76 | 77.8 ± 10.02 | 69.6 ± 11.48 | 80.9 ± 8.21 | 75.1 ± 5.77 | 77.1 ± 12.00 | 80.3 ± 7.83 |
| Sitting diastolic BP: change at week 2 | -1.6 ± 8.49 | 0.7 ± 7.93 | 0.0 ± 9.44 | 1.6 ± 12.00 | -2.9 ± 10.77 | 1.7 ± 8.20 | 4.5 ± 5.80 | -1.2 ± 6.49 |
| Sitting diastolic BP: change at week 6 | 0.8 ± 9.90 | 0.0 ± 5.79 | -1.6 ± 11.97 | 1.1 ± 15.61 | -5.3 ± 9.27 | -2.8 ± 12.60 | -0.3 ± 7.89 | 0.4 ± 8.41 |
| Beats per minute | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Baseline | 69.6 ± 12.58 | 69.5 ± 9.82 | 72.9 ± 14.30 | 67.9 ± 9.31 | 68.8 ± 11.76 | 69.4 ± 11.15 | 70.1 ± 11.18 | 68.2 ± 9.59 |
| Change at week 2 | 0.5 ± 10.41 | 0.2 ± 8.11 | -2.5 ± 9.66 | 1.1 ± 9.13 | 0.5 ± 6.54 | 3.7 ± 9.47 | 2.8 ± 8.28 | 4.1 ± 9.16 |
| Change at week 6 | 2.1 ± 10.59 | 0.3 ± 8.04 | -1.4 ± 11.90 | 0.9 ± 9.71 | 1.8 ± 8.73 | 4.1 ± 6.76 | 0.5 ± 9.12 | 1.8 ± 8.64 |
| Degree Celsius | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Baseline | 36.5 ± 0.33 | 36.5 ± 0.43 | 36.6 ± 0.44 | 36.6 ± 0.33 | 36.5 ± 0.37 | 36.5 ± 0.29 | 36.6 ± 0.41 | 36.6 ± 0.29 |
| Change at week 2 | -0.1 ± 0.41 | -0.1 ± 0.30 | 0.0 ± 0.38 | -0.0 ± 0.43 | 0.1 ± 0.35 | -0.0 ± 0.38 | 0.0 ± 0.34 | 0.0 ± 0.41 |
| Change at week 6 | -0.0 ± 0.40 | -0.0 ± 0.29 | 0.0 ± 0.38 | 0.1 ± 0.32 | 0.0 ± 0.29 | 0.1 ± 0.50 | 0.0 ± 0.37 | -0.0 ± 0.46 |
Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent \[if still in place\]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.
| Participants | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| Day 1: tolerability before: none | 35 | 35 | 31 | 33 | 36 | 35 | 34 | 36 |
| Day 1: tolerability before: mild | 0 | 0 | 1 | 3 | 0 | 1 | 2 | 0 |
| Day 1: tolerability before: moderate | 2 | 2 | 4 | 1 | 0 | 0 | 0 | 1 |
| Day 1: tolerability after: none | 33 | 36 | 30 | 33 | 35 | 34 | 32 | 33 |
| Day 1: tolerability after: mild | 1 | 0 | 1 | 2 | 0 | 2 | 4 | 1 |
| Day 1: tolerability after: moderate | 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| Week 1: tolerability before: none | 31 | 28 | 28 | 30 | 30 | 30 | 33 | 33 |
| Week 1: tolerability before: mild | 1 | 2 | 3 | 3 | 3 | 1 | 1 | 1 |
| Week 1: tolerability before: moderate | 2 | 0 | 3 | 0 | 0 | 1 | 0 | 0 |
| Week 1: tolerability after: none | 28 | 29 | 29 | 30 | 28 | 27 | 32 | 31 |
| Week 1: tolerability after: mild | 2 | 2 | 2 | 3 | 2 | 3 | 1 | 1 |
| Week 1: tolerability after: moderate | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 |
| Week 2: tolerability before: none | 29 | 28 | 26 | 30 | 30 | 23 | 31 | 33 |
| Week 2: tolerability before: mild | 3 | 2 | 2 | 2 | 1 | 1 | 0 | 0 |
| Week 2: tolerability before: moderate | 1 | 0 | 3 | 1 | 0 | 0 | 1 | 0 |
| Week 2: tolerability after: none | 28 | 26 | 29 | 31 | 29 | 23 | 32 | 30 |
| Week 2: tolerability after: mild | 1 | 3 | 2 | 1 | 1 | 2 | 0 | 1 |
| Week 2: tolerability after: moderate | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Week 4: tolerability before: none | 27 | 26 | 30 | 30 | 30 | 24 | 31 | 31 |
| Week 4: tolerability before: mild | 0 | 2 | 2 | 2 | 0 | 0 | 1 | 1 |
| Week 4: tolerability before: moderate | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Week 4: tolerability after: none | 24 | 26 | 30 | 30 | 29 | 24 | 31 | 30 |
| Week 4: tolerability after: mild | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 0 |
| Week 4: tolerability after: moderate | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Week 6: tolerability before: none | 26 | 25 | 29 | 30 | 30 | 21 | 30 | 32 |
| Week 6: tolerability before: mild | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 1 |
| Week 6: tolerability before: moderate | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| Week 6: tolerability after: none | 25 | 24 | 28 | 29 | 29 | 22 | 30 | 30 |
| Week 6: tolerability after: mild | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Week 6: tolerability after: moderate | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Early termination:tolerability: none | 6 | 5 | 3 | 2 | 2 | 9 | 2 | 1 |
| Early termination:tolerability: mild | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Early termination:tolerability: moderate | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Early termination:tolerability: severe | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Follow Up: tolerability: none | 22 | 26 | 25 | 25 | 28 | 25 | 26 | 28 |
| Follow Up: tolerability: mild | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 1 |
| Follow Up: tolerability: moderate | 1 | 0 | 1 | 4 | 1 | 1 | 0 | 0 |
| Follow Up: tolerability: severe | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Collected over Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream Once Daily (QD) | 0/37 (0%) | 0/37 (0%) | 18/37 (48.6%) |
| PF-06700841 0.1% Cream QD | 0/37 (0%) | 0/37 (0%) | 17/37 (45.9%) |
| PF-06700841 0.3% Cream QD | 0/36 (0%) | 0/36 (0%) | 11/36 (30.6%) |
| PF-06700841 1.0% Cream QD | 0/37 (0%) | 0/37 (0%) | 12/37 (32.4%) |
| PF-06700841 3.0% Cream QD | 0/36 (0%) | 0/36 (0%) | 10/36 (27.8%) |
| Vehicle Cream Twice Daily (BID) | 0/36 (0%) | 0/36 (0%) | 17/36 (47.2%) |
| PF-06700841 0.3% Cream BID | 0/36 (0%) | 0/36 (0%) | 9/36 (25%) |
| PF-06700841 1.0% Cream BID | 0/37 (0%) | 0/37 (0%) | 14/37 (37.8%) |
| Event | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/37 | 2/37 | 2/36 | 3/37 | 4/36 | 2/36 | 2/36 | 2/37 |
| Application site pruritusGeneral disorders | 0/37 | 0/37 | 0/36 | 0/37 | 0/36 | 3/36 | 0/36 | 0/37 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 3/37 | 3/37 | 1/36 | 0/37 | 1/36 | 3/36 | 0/36 | 2/37 |
| Application site erythemaGeneral disorders | 0/37 | 0/37 | 0/36 | 0/37 | 0/36 | 2/36 | 0/36 | 1/37 |
| Urinary tract infectionInfections and infestations | 1/37 | 0/37 | 2/36 | 2/37 | 0/36 | 0/36 | 0/36 | 0/37 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/37 | 0/37 | 2/36 | 0/37 | 0/36 | 1/36 | 1/36 | 0/37 |
| InfluenzaInfections and infestations | 0/37 | 1/37 | 0/36 | 2/37 | 1/36 | 0/36 | 0/36 | 0/37 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/37 | 2/37 | 1/36 | 0/37 | 0/36 | 0/36 | 0/36 | 0/37 |
| PruritusSkin and subcutaneous tissue disorders | 2/37 | 1/37 | 0/36 | 0/37 | 0/36 | 0/36 | 0/36 | 0/37 |
| Swelling of eyelidEye disorders | 0/37 | 0/37 | 0/36 | 0/37 | 0/36 | 0/36 | 1/36 | 0/37 |
Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.
| Age, Continuous(Years) | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 39.1 ± 16.80 | 40.8 ± 15.35 | 43.4 ± 16.43 | 38.4 ± 12.90 | 40.5 ± 12.30 | 42.3 ± 18.18 | 39.4 ± 17.27 | 38.1 ± 15.34 | 40.2 ± 15.59 |
| Sex: Female, Male(Participants) | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 20 | 19 | 24 | 23 | 15 | 19 | 16 | 20 | 156 |
| Male | 17 | 18 | 12 | 14 | 21 | 17 | 20 | 17 | 136 |
| Ethnicity (NIH/OMB)(Participants) | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 3 | 2 | 1 | 3 | 0 | 4 | 13 |
| Not Hispanic or Latino | 37 | 37 | 32 | 35 | 35 | 33 | 35 | 33 | 277 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Vehicle Cream Once Daily (QD) | PF-06700841 0.1% Cream QD | PF-06700841 0.3% Cream QD | PF-06700841 1.0% Cream QD | PF-06700841 3.0% Cream QD | Vehicle Cream Twice Daily (BID) | PF-06700841 0.3% Cream BID | PF-06700841 1.0% Cream BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 8 | 4 | 8 | 10 | 9 | 9 | 7 | 59 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Black or African American | 8 | 7 | 9 | 6 | 4 | 6 | 5 | 6 | 51 |
| White | 24 | 22 | 21 | 20 | 21 | 20 | 22 | 24 | 174 |
| More than one race | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 5 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from May 2019 to primary completion in May 2020, 11 months.
Results were first posted in Mar 2021, 10 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841